SWITCHING TO A PROTEASE INHIBITOR-CONTAINING, NUCLEOSIDE-SPARING REGIMEN

改用含有蛋白酶抑制剂、保留核苷的治疗方案

• 批准号: 7953991
• 负责人: PABLO TEBAS
• 金额: $ 0.51万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-01 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7953991
• 关键词: Adverse effects; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Cells; Complication; Computer Retrieval of Information on Scientific Projects Database; Development; Dose; Fatty acid glycerol esters; Funding; Grant; HIV; Institution; Limb structure; Link; Lipoatrophy; Lopinavir/Ritonavir; Mass Spectrum Analysis; Metabolic; Nucleosides; Participant; Protease Inhibitor; RNA; Randomized; Research; Research Personnel; Resources; Source; Treatment Protocols; United States National Institutes of Health; Upper arm; Viral Load result; biomedical resource; efavirenz; nucleoside analog; open label; subcutaneous

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. BACKGROUND: Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication. METHODS: We evaluated the effects of nucleoside-sparing and PI-sparing regimens on fat distribution, bone mineral density, and metabolic parameters in 62 subjects, who were not selected for lipoatrophy, with advanced HIV (nadir CD4 count <or=200 cells/mm or HIV RNA level >or=80,000 copies/mL) and an undetectable HIV viral load. Participants were randomized to switch their initial successful antiretroviral regimen to open-label lopinavir/ritonavir (LPV/r) at a dose of 533/133 mg twice a day and efavirenz (EFV) at a dose of 600 mg/d (the nucleoside-sparing arm) versus EFV and 2 nucleoside analogues (the PI-sparing arm).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 背景：肢体皮下脂肪减少仍然是长期抗逆转录病毒疗法最令人不安的副作用之一。核苷类似物和蛋白酶抑制剂 (PI) 与这种并发症的发生有关。方法：我们评估了 62 名晚期 HIV 受试者（最低 CD4 计数<或=200 个细胞/ mm 或 HIV RNA 水平 > 或 = 80,000 拷贝/mL）以及无法检测到的 HIV 病毒载量。参与者被随机化，将他们最初成功的抗逆转录病毒治疗方案改为开放标签洛匹那韦/利托那韦（LPV/r），剂量为 533/133 mg，每天两次，以及依非韦伦（EFV），剂量为 600 mg/d（核苷-保留臂）与 EFV 和 2 个核苷类似物（PI 保留臂）。